两家A股公司"戴帽"。 同日，贵州证监局对贵州百灵企业集团制药股份有限公司涉嫌定期报告财务数据存在虚假记载作出行政 处罚及市场禁入事先告知。经查，贵州百灵未以权责发生制为基础，按照收入成本费用配比原则确认当 期销售费用，导致2019年至2021年期间少计销售费用，累计虚增利润65472.60万元，2023年多计销售费 用，虚减利润45941.10万元。对贵州百灵多年财务造假，严重违反证券法律法规行为，贵州证监局依法 拟对贵州百灵责令改正，给予警告,处以1000万元罚款；拟对姜伟等10名责任人给予警告，处以罚款合 计1560万元，同时拟对姜伟采取10年证券市场禁入措施。 截至今日收盘，贵州百灵股价上涨1.81%，报收5.63元/股，总市值为78.68亿元。 截至今日收盘，福能东方股价上涨2.66%，报收5.41元/股，总市值为39.75亿元。 贵州百灵(002424.SZ)公告称，公司及相关人员收到贵州证监局的《行政处罚事先告知书》，公司披露 的2019年、2020年、2021年、2023年年报存在虚假记载。根据深圳证券交易所股票上市规则，公司股票 将被实施其他风险警示，股票简称由"贵州百灵"变更为"ST百灵" ...

截至今日收盘，贵州百灵股价上涨1.81%，报收5.63元/股，总市值为78.68亿元。 责编：叶舒筠 校对： 姚远 版权声明 证券时报各平台所有原创内容，未经书面授权，任何单位及个人不得转载。我社保留追 究相关 行 为主体 法律责任的权利。 两家A股公司"戴帽"。 12月19日，福能东方(300173.SZ)公告称，公司于2025年12月19日收到广东证监局下发的《行政处罚 事先告知书》。根据中国证监会行政处罚事先告知书载明的事实，公司披露的年度报告财务指标存在虚 假记载，但未触及第10.5.2条第一款规定情形，前述财务指标包括营业收入、利润总额、净利润、资产 负债表中的资产或者负债科目，公司股票将被实施其他风险警示。股票简称由"福能东方"变更为"ST福 能"，股票代码不变，仍为"300173"。公司股票自2025年12月22日开市起停牌1天，将于2025年12月 23日开市起复牌。 截至今日收盘， 福能东方股价上涨2.66%，报收5.41元/股，总市值为39.75亿元。 贵州百灵(002424.SZ)公告称，公司及相关人员收到贵州证监局的《行政处罚事先告知书》，公司披露 的2019年、2020年、2021年 ...

同日，苗药龙头股贵州百灵发布公告，贵州百灵及相关当事人收到贵州证监局出具的《行政处 罚事先告知书》，因贵州百灵披露的2019年至2021年及2023年年报存在虚假记载，深圳证券 交易所将对贵州百灵股票实施其他风险警示。 贵州百灵股票 自2025年12月22日开市起停牌一天，并于2025年12月23日开市复牌。 自2025年 12月23日开市起，贵州百灵股票简称由"贵州百灵" 变更为"ST百灵" ，股票代码不变，仍 为"002424"，股票交易日涨跌幅限制由10%变为5%。 截至12月19日，贵州百灵股价报5.63元，总市值79亿元，今年以来累计上涨超46%。 贵州百灵财务造假遭重罚 对此你有什么想说的？ 欢迎评论区聊聊~ （声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担。） 出品丨21财经客户端 21世纪经济报道 理想汽车组织架构调整，涉近千人，原零部件负责人离职 热搜第一，牛股瞬间闪崩12个点，网友：炒股用曲面屏太难受 SFC 21君荐读 记者丨曾静娇 编辑丨刘雪莹 12月19日晚间，据贵州证监局网站消息，近日，贵州证监局对贵州百灵企业集团制药股份有限 公司(以下简称"贵州百灵")涉嫌定期 ...

Core Viewpoint - Guizhou BaiLing (002424) is facing severe penalties from the China Securities Regulatory Commission (CSRC) due to violations related to financial disclosures, leading to significant fines and management repercussions [1][4][9]. Financial Misconduct - Guizhou BaiLing has been found guilty of financial misconduct over four years, with false records in annual reports leading to penalties [4]. - The company failed to adhere to the accounting standards, resulting in understated sales expenses and overstated profits for the years 2019, 2020, 2021, and 2023 [4]. - Specific figures include: - 2019: Understated sales expenses by 350.12 million, overstated profits by 350.12 million, 95.73% of reported profit [4] - 2020: Understated sales expenses by 240.81 million, overstated profits by 240.81 million, 115.35% of reported profit [4] - 2021: Understated sales expenses by 63.79 million, overstated profits by 63.79 million, 45.04% of reported profit [4] - 2023: Overstated sales expenses by 459.41 million, understated profits by 459.41 million, 93.17% of reported profit [4] Penalties and Management Accountability - The CSRC has proposed a fine of 10 million for Guizhou BaiLing and a warning for the company to rectify its practices [4]. - The former chairman, Jiang Wei, is facing a 5 million fine and a 10-year ban from the securities market due to his direct involvement in the misconduct [5]. - Other executives are also facing fines ranging from 60,000 to 3.5 million, reflecting the severity of their roles in the financial misreporting [6][7]. Stock Market Impact - Starting December 23, the company's stock will be renamed "ST BaiLing" and will face additional risk warnings due to the financial misconduct [10]. - The company has confirmed that it has not reached conditions for mandatory delisting but will be under increased scrutiny [10]. Company Operations - Despite the ongoing issues, Guizhou BaiLing has stated that its production and business activities remain normal [11]. - The company has committed to improving internal controls and governance to prevent future violations [11]. Recent Performance - For the first three quarters of 2025, Guizhou BaiLing reported a revenue of 2.102 billion, a decrease of 24.28% year-on-year, and a net profit of 56.81 million, down 35.60% year-on-year [13].

近日，中国证券监督管理委员会贵州监管局(以下简称贵州证监局)对贵州百灵企业集团制药股份有限公 司(以下简称贵州百灵)涉嫌定期报告财务数据存在虚假记载作出行政处罚及市场禁入事先告知。 财务造假是严重破坏市场"三公"原则，侵害投资者合法权益的毒瘤。贵州证监局将坚决贯彻证监会党委 的各项决策部署，着力提升监管执法的有效性和震慑力，坚持对财务造假"零容忍"打击的鲜明立场，聚 焦打大、打恶、打重点，紧盯实控人、控股股东、董事、高管等"关键少数"和中介机构"看门人"，严格 执法、秉公执法，坚决做到监管"长牙带刺"、有棱有角，以有力监管执法护航贵州资本市场行稳致远。 来源｜证监会网站 经查，贵州百灵未以权责发生制为基础，按照收入成本费用配比原则确认当期销售费用，导致2019年至 2021年期间少计销售费用，累计虚增利润65472.60万元，2023年多计销售费用，虚减利润45941.10万 元。对贵州百灵多年财务造假，严重违反证券法律法规行为，贵州证监局依法拟对贵州百灵责令改正， 给予警告，处以1000万元罚款;拟对姜伟等10名责任人给予警告，处以罚款合计1560万元，同时拟对姜 伟采取10年证券市场禁入措施。 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) imposed a fine of 3 million yuan on Qingdao Damo Securities Investment Co., Ltd. and revoked its securities investment consulting business license due to serious violations of regulations [1][9]. Group 1: Violations and Penalties - Damo Investment failed to properly maintain and destroyed relevant documents and materials, leading to significant omissions in reports submitted to the securities regulatory authority [4][7]. - The company reported a total of 485 million yuan in unreported operating income from September 2022 to August 2024, indicating severe violations with a large number of affected clients [5][7]. - Four responsible individuals received penalties, including warnings and fines ranging from 30,000 to 600,000 yuan, highlighting the accountability of management and operational staff [9][10]. Group 2: Regulatory Context - The revocation of the business license is considered a "top-tier penalty" for licensed securities investment consulting firms, which is more severe than a monetary fine [10]. - Recent regulatory actions indicate a tightening stance on securities investment consulting firms, as evidenced by similar penalties imposed on other firms like Beijing Zhongfang Xinfeng Investment Management Consulting Co., Ltd. [11].

12月19日晚间，据贵州证监局网站消息，近日，贵州证监局对贵州百灵企业集团制药股份有限公司(以 下简称"贵州百灵")涉嫌定期报告财务数据存在虚假记载作出行政处罚及市场禁入事先告知。 贵州百灵股票自2025年12月22日开市起停牌一天，并于2025年12月23日开市复牌。自2025年12月23日开 市起，贵州百灵股票简称由"贵州百灵"变更为"ST百灵"，股票代码不变，仍为"002424"，股票交易日涨 跌幅限制由10%变为5%。 截至12月19日，贵州百灵股价报5.63元，总市值79亿元，今年以来累计上涨超46%。 （文章来源：21世纪经济报道） 经查，贵州百灵未以权责发生制为基础，按照收入成本费用配比原则确认当期销售费用，导致2019年至 2021年期间少计销售费用，累计虚增利润65472.60万元，2023年多计销售费用，虚减利润45941.10万 元。 对贵州百灵多年财务造假，严重违反证券法律法规行为，贵州证监局依法拟对贵州百灵责令改正，给予 警告，处以1000万元罚款；拟对姜伟等10名责任人给予警告，处以罚款合计1560万元，同时拟对姜伟采 取10年证券市场禁入措施。 同日，苗药龙头股贵州百灵发布公告， ...

12月19日晚间，据贵州证监局网站消息，近日，贵州证监局对贵州百灵（002424）企业集团制药股份有限公司(以下 简称"贵州百灵")涉嫌定期报告财务数据存在虚假记载作出行政处罚及市场禁入事先告知。 经查，贵州百灵未以权责发生制为基础，按照收入成本费用配比原则确认当期销售费用，导致2019年至2021年期间少 计销售费用，累计虚增利润65472.60万元，2023年多计销售费用，虚减利润45941.10万元。 对贵州百灵多年财务造假，严重违反证券法律法规行为，贵州证监局依法拟对贵州百灵责令改正，给予警告，处以 1000万元罚款；拟对姜伟等10名责任人给予警告，处以罚款合计1560万元，同时拟对姜伟采取10年证券市场禁入措 施。 同日，苗药龙头股贵州百灵发布公告，贵州百灵及相关当事人收到贵州证监局出具的《行政处罚事先告知书》，因贵 州百灵披露的2019年至2021年及2023年年报存在虚假记载，深圳证券交易所将对贵州百灵股票实施其他风险警示。 贵州百灵股票自2025年12月22日开市起停牌一天，并于2025年12月23日开市复牌。自2025年12月23日开市起，贵州百 灵股票简称由"贵州百灵"变更为"ST百灵"， ...

Core Viewpoint - Three A-share listed companies received administrative penalty notices from regulatory authorities for financial fraud, raising market concerns [1] Group 1: Guizhou Bailin - Guizhou Bailin reported false records in its annual reports for 2019, 2020, 2021, and 2023, leading to a warning and a change in stock designation to "ST Bailin" with a trading limit of 5% [2] - The company was found to have understated sales expenses, resulting in an inflated profit of 654.726 million yuan from 2019 to 2021, and overstated sales expenses in 2023, reducing profit by 459.411 million yuan [2] - Guizhou Securities Regulatory Bureau proposed a fine of 10 million yuan for the company and a total of 15.6 million yuan for 10 responsible individuals, with a 10-year market ban for one individual [2] Group 2: Funu Dongfang - Funu Dongfang received an administrative penalty notice for false records in its annual reports for 2020 and 2021 [5] - The company was involved in a scheme that inflated profits by 35.798 million yuan in 2020, which was 120.18% of the reported profit, and reduced profits by 22.651 million yuan in 2021, accounting for 6.64% of the reported profit [6] - The stock designation will change to "ST Funu" with a trading halt for one day starting December 22, 2025 [7] Group 3: ST Yuanzhi - ST Yuanzhi was penalized for false records in its annual reports from 2019 to 2022, with a fine of 6 million yuan imposed [10] - The company falsely recognized sales revenue from elevator sales using forged acceptance certificates, inflating revenue by 123.238 million yuan in 2019, 66.226 million yuan in 2020, and 138.250 million yuan in 2021 [11] - The company also inflated revenue by 9.148 million yuan in 2021 from a lease agreement that was never executed, leading to a profit inflation of 8.482 million yuan, which was 62.47% of the reported profit [12]

Group 1 - The core issue involves Guizhou Bailing's financial fraud, leading to administrative penalties from the Guizhou Securities Regulatory Bureau [1] - Guizhou Bailing's financial reports for 2019, 2020, 2021, and 2023 contained false records, resulting in a cumulative profit inflation of 65,472.60 million yuan and a profit reduction of 45,941.10 million yuan in 2023 [1] - The company will face a fine of 10 million yuan and warnings for its financial misconduct, while 10 responsible individuals, including Jiang Wei, will be fined a total of 15.6 million yuan and face a 10-year market ban [1] Group 2 - The Guizhou Securities Regulatory Bureau emphasizes a zero-tolerance policy towards financial fraud, aiming to enhance regulatory effectiveness and protect investor rights [2] - Guizhou Bailing is a pharmaceutical company involved in the research, production, and sales of traditional medicine, with key products including Yindan Xinnaotong soft capsules and Kesu Ting syrup [2]